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ABSTRACT
Background Several regions of the genome have
shown to be associated with COPD in genome-wide
association studies of common variants.
Objective To determine rare and potentially
functional single nucleotide polymorphisms (SNPs)
associated with the risk of COPD and severity of airﬂow
limitation.
Methods 3226 current or former smokers of European
ancestry with lung function measures indicative of Global
Initiative for Chronic Obstructive Lung Disease (GOLD) 2
COPD or worse were genotyped using an exome array.
An analysis of risk of COPD was carried out using ever
smoking controls (n=4784). Associations with %
predicted FEV1 were tested in cases. We followed-up
signals of interest (p<10−5) in independent samples
from a subset of the UK Biobank population and also
undertook a more powerful discovery study by meta-
analysing the exome array data and UK Biobank data for
variants represented on both arrays.
Results Among the associated variants were two in
regions previously unreported for COPD; a low frequency
non-synonymous SNP in MOCS3 (rs7269297,
pdiscovery=3.08×10
−6, preplication=0.019) and a rare SNP
in IFIT3, which emerged in the meta-analysis
(rs140549288, pmeta=8.56×10
−6). In the meta-analysis
of % predicted FEV1 in cases, the strongest association
was shown for a splice variant in a previously
unreported region, SERPINA12 (rs140198372,
pmeta=5.72×10
−6). We also conﬁrmed previously
reported associations with COPD risk at MMP12, HHIP,
GPR126 and CHRNA5. No associations in novel regions
reached a stringent exome-wide signiﬁcance threshold
(p<3.7×10−7).
Conclusions This study identiﬁed several associations
with the risk of COPD and severity of airﬂow limitation,
including novel regions MOCS3, IFIT3 and SERPINA12,
which warrant further study.
INTRODUCTION
COPD is a major public health concern, being a
leading cause of morbidity and mortality world-
wide.1 The Global Initiative for Chronic
Obstructive Lung Disease (GOLD) recommends
that the impact of COPD on an individual patient
should assessed by considering breathlessness,
symptoms and exacerbation risk, in combination
with the severity of airﬂow limitation, which can be
graded using %predicted FEV1.
2 Approximately
1%–2% of COPD cases can be attributed to
α1-antitrypsin (AAT) deﬁciency, a rare inherited
disorder, caused by mutations within the
SERPINA1 gene.3 4 For the remainder of COPD
cases, cigarette smoking is recognised as the most
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What is the key question?
▸ Do low frequency exonic variants inﬂuence
susceptibility to COPD, and severity of airﬂow
limitation?
What is the bottom line?
▸ Low frequency single nucleotide polymorphisms
(SNPs) in MOCS3 and IFIT3 were associated
with risk of COPD and a rare splice variant in
SERPINA12 was associated with severity of
airﬂow limitation.
Why read on?
▸ These genomic regions have not previously
been implicated in lung function or COPD and
these ﬁndings could therefore provide further
insight into COPD susceptibility and severity.
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signiﬁcant risk factor5; however, there is also a genetic compo-
nent, with several genomic regions showing association with
COPD risk or airﬂow limitation to date, including CHRNA3/5,
HHIP,3 HTR4, GSTCD, TNS1,6 MMP127 8 and FAM13A.9
COPD diagnosis is conﬁrmed using measures of lung function,
so it is likely that the genetic determinants of COPD and lung
function will overlap. Indeed, many loci identiﬁed in large
genome-wide association studies (GWAS) of FEV1 and the ratio
of FEV1 to forced vital capacity (FEV1/FVC) in general popula-
tion samples10–13 have subsequently being shown to be asso-
ciated with COPD or airﬂow limitation.6 9 14 15
Despite the successes in identifying genes associated with lung
function and COPD, these known loci only explain a small pro-
portion of the expected heritability.13 Large GWAS undertaken
to date have generally focused on common variants (typically
>5% minor allele frequency (MAF))3 9–14; one hypothesis is
that some of the so-called ‘missing heritability’ might be
accounted for by variants of lower frequencies. In this study, we
set out to investigate the role of low frequency, functional var-
iants in COPD, and to conﬁrm the role of single nucleotide
polymorphisms (SNPs) previously showing association with lung
function. It is hypothesised that rare variants are more likely
than common variants to have deleterious effects; identifying
such SNPs could lead to greater understanding of the pathways
and biological mechanisms underlying airﬂow obstruction and
COPD, and could translate to novel targets for treatment.
We genotyped cases with a history of smoking and airﬂow
limitation, indicative of GOLD 2 COPD or worse, and control
samples using an exome chip array to which we had added
custom content comprising 2585 SNPs tagging regions which
had shown suggestive association (p<2.21×10−3) with lung
function in a previous large genome-wide HapMap-imputed
study.13 The exome chip genotyping array design contains
mostly non-synonymous, splice or stop codon altering variants
that are likely to affect protein structure and function, with the
majority of variants being low frequency (MAF 1%–5%) or rare
(MAF<1%).
In this study, we carried out discovery case–control analyses
(COPD cases vs controls) and analyses of %predicted FEV1 in
cases, as a measure of severity of airﬂow limitation. Replication
was undertaken using a subset of the UK Biobank Lung Exome
Variant Evaluation (BiLEVE) study, a collection of 48 931 indivi-
duals from UK Biobank with high-quality lung function and
smoking data who were genotyped on an array that includes
substantial overlap with the exome chip.16 We also adopted a
more powerful discovery strategy for COPD risk and severity of
airﬂow limitation, by meta-analysing data for the subset of
exome chip variants that were measured in both the COPD
exome chip consortium and the UK BiLEVE study.
METHODS
Study participants and phenotypes
A total of 3487 ever smokers with airﬂow limitation indicative
of GOLD 22 COPD or worse were identiﬁed from 12 UK col-
lections as cases (case collections described in online supplemen-
tary table S1). Individuals met case criteria if they had FEV1/
FVC ≤0.7 and %predicted FEV1 ≤80% (according to the
National Health and Nutrition Examination Survey (NHANES)
III spirometric reference equations17), did not have a doctor
diagnosis of asthma and had reported current, or former
smoking. Five of the sample collections (n=1398 samples, table
1) were COPD cohorts, with all individuals having irreversible
airﬂow limitation, and meeting GOLD 2 criteria based on post-
bronchodilator spirometry. The remaining cases were taken
from general population cohorts; for these samples, only pre-
bronchodilator spirometry measures were available. We used
general population controls with exome chip data, from
Generation Scotland: Scottish Family Health Study (GS:SFHS),
British 1958 Birth Cohort (1958BC), Oxford Biobank and
GoDARTS (Genetics of Diabetes and Audit Research Tayside
Study), listed in table 1 with clinical characteristics. All controls
were current or former smokers and were free of lung disease,
according to available spirometry and phenotype information.
We used a subset of the UK BiLEVE study16 for replication of
novel signals, and for a larger discovery meta-analysis. A total of
24 457 heavy smokers (mean 35 pack-years) were genotyped as
part of the UK BiLEVE study, selected such that 9748 indivi-
duals formed a low FEV1 group (based on %predicted FEV1),
4906 individuals formed a high FEV1 group and 9803 had
average FEV1. We selected 4231 samples from the low FEV1
group, with airﬂow limitation consistent with GOLD 2 or worse
as cases and 8979 samples from the high and average FEV1
groups with FEV1/FVC >0.7, %predicted FEV1 >80% and no
doctor diagnosis of COPD for use as controls. All spirometry
measures were prebronchodilator, all samples were heavy
smokers and individuals with a doctor diagnosis of asthma or
other lung diseases were excluded. The %predicted FEV1 was
estimated using NHANES III spirometric reference equations.17
An overview of the full study design is shown in ﬁgure 1.
Genotyping
All 3487 cases and 1032 GS:SFHS controls were genotyped
together using the Illumina Human Exome BeadChip with add-
itional custom content for regions which have previously shown
modest association with lung function (description of custom
content design in online supplementary methods). The remain-
ing discovery analyses control samples were genotyped separ-
ately using the Illumina Human Exome BeadChip.
The UK BiLEVE samples were genotyped using the
Affymetrix UK BiLEVE array, which includes rare variants
selected from the same sequencing project as the Illumina
Human Exome BeadChip alongside additional content.16 Of
the 807 411 SNPs included on the Affymetrix UK BiLEVE
array, 74 891 were also present on the Illumina Human Exome
BeadChip; this subset of SNPs, which were directly genotyped
on both arrays, was selected for the discovery meta-analysis.
Quality control of genotype data
Discovery exome analysis
Genotypes were called using Illumina’s Gencall algorithm in
Genomestudio18 with reﬁnement of rare variants with missing
calls undertaken using zCall.19 Standard quality control (QC)
ﬁlters were applied, in accordance with the Exome-chip Quality
Control SOP V.5, as developed within the UK exome chip con-
sortium20 and are fully described in online supplementary
methods. In brief, SNPs were excluded if they had low call rate
(<99%) or deviated from Hardy Weinberg Equilibrium
(p<10−4) and samples were excluded if they were duplicates,
sex mismatches, heterozygosity outliers (>3 SD from mean),
had an excess of singleton SNPs, or were ancestral outliers.
Clusterplots for all SNPs of interest were inspected, to ensure
accuracy of genotype calling.
UK BiLEVE data
The QC procedure of the UK BiLEVE genotype data is
described elsewhere.16
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Table 1 Clinical characteristics of samples passing genotype QC
Sex Age %Predicted FEV1 FEV1/FVC
Pack-years
Sample collection n Male, n (%) Mean (SD) Mean (SD) Mean (SD)
Samples with data
(n) Mean (SD)
Discovery analyses airflow limitation cases (total n=3226, with pack-years n=2517)
GS:SFHS 508 224 (44.1%) 58.9 (8.94) 64.84 (12.64) 0.580 (0.108) 482 29.32 (24.96)
British Regional Heart Study 425 425 (100%) 70.1 (5.46) 59.41 (14.66) 0.597 (0.084) 0 –
British Women’s Heart and Health Study 254 0 (0%) 69.3 (5.46) 64.26 (12.40) 0.603 (0.074) 203 28.1 (18.36)
UK COPD cohort* 209 129 (61.7%) 68.7 (8.11) 37.94 (15.29) 0.447 (0.119) 199 50.07 (27.79
Hertfordshire Cohort Study 317 203 (64.0%) 66.1 (2.79) 62.89 (13.57) 0.589 (0.101) 312 32.25 (23.37)
COPDBEAT* 87 62 (71.3%) 67.6 (8.77) 45.19 (16.24) 0.480 (0.115) 86 38.69 (21.24)
Nottingham COPD study* 76 48 (63.2%) 67.2 (8.97) 50.29 (15.04) 0.482 (0.111) 74 49.02 (26.86)
Nottingham smokers 125 78 (62.4%) 63.1 (8.60) 46.27 (17.65) 0.503 (0.125) 124 41.75 (20.61)
Gedling study 33 26 (78.8%) 69.0 (8.23) 59.67 (16.81) 0.593 (0.103) 31 45.47 (33.40)
English Longitudinal Study of Aging 166 75 (45.2%) 66.0 (8.17) 54.84 (17.24) 0.526 (0.149) 0 –
EU COPD Gene Scan* 277 155 (56.0%) 67.0 (8.68) 38.51 (14.74) 0.467 (0.120) 277 46.43 (20.56)
GoTARDIS Study* 749 412 (55.0%) 68.8 (8.97) 52.16 (14.14) 0.509 (0.110) 729 43.26 (21.59)
Discovery analyses controls (total n=4784, with pack-years n=3889)
GS:SFHS 961 552 (57.4%) 54.5 (8.41) 98.18 (10.92) 0.783 (0.051) 961 28.92 (16.86)
British 1958 Birth Cohort 1429 888 (62.1%) 44 (0) 100.90 (13.46) 0.809 (0.060) 1046 14.74 (10.07)
Oxford Biobank 1770 832 (47.0%) 41.6 (5.77) – – 1682 9.09 (9.34)
GoDARTS 624 402 (64.4%) 59.0 (10.75) – – 200 35.46 (25.89)
UK Biobank Lung Exome Variant Evaluation samples (meta-analysis and replication)
Airflow limitation cases 4231 2379 (56.2%) 59.54 (6.86) 61.76 (11.8) 0.607 (0.076) 4231 42.41 (21.10)
Controls 8979 4260 (47.4%) 56.19 (7.92) 101.40 (8.1) 0.773 (0.038) 8979 30.43 (14.41)
*Sample collection is COPD case cohort.
GS:SFHS, Generation Scotland: Scottish Family Health Study; GoTARDIS, Tayside Allergy and Respiratory Disease Information System; QC, quality control.
Figure 1 Two-stage study design. Stage 1: exome discovery analyses. Stage 2: Follow-up in UK BiLEVE: A. Replication of signals; B. meta-analysis
of UK COPD exome chip consortium and UK BiLEVE.
Jackson VE, et al. Thorax 2016;71:501–509. doi:10.1136/thoraxjnl-2015-207876 503
Chronic obstructive pulmonary disease
group.bmj.com on June 23, 2016 - Published by http://thorax.bmj.com/Downloaded from 
Statistical analyses
SNP associations with COPD risk were carried out using a logis-
tic regression model, adjusting for age, sex and pack-years and
assuming an additive genetic model. Associations with untrans-
formed %predicted FEV1 in cases were tested, using a linear
regression model, with adjustment for pack-years (analysis of
severity of airﬂow limitation). Since not all samples had pack-
years data available, secondary analyses were carried out
without adjustment for pack-years, for both the COPD risk and
severity of airﬂow limitation analyses, allowing the inclusion of
all samples. Single variant analyses were carried out using
PLINK V.1.07.21 Using a Bonferroni correction for the number
of tests undertaken, a signiﬁcance level of p<3.7×10−7 would
be required in the exome single variant analysis to retain a type
1 error of 5%. We deﬁned SNPs of interest as those with
p<10−5 in the discovery exome analysis; for these SNPs, we
undertook replication analyses in the UK BiLEVE study to cor-
roborate ﬁndings (see online supplementary methods). We set a
Bonferroni corrected signiﬁcance level for replication, for the
number of SNPs in novel loci taken forward to replication
(p<0.017 for analysis of COPD risk). Gene-based analyses
using SKAT-O were additionally undertaken; the methods and
results of these analyses are described in the online supplemen-
tary information.
Custom content single variant analyses
Custom content comprising 2585 SNPs tagging regions which
had shown suggestive association (p<2.21×10−3) with lung
function in a previous large genome-wide HapMap-imputed
study13 were also included on the array for cases and GS:SFHS
controls. Additional controls from 1958BC and Busselton
Health Study (BHS) with genome-wide data were also used; full
methods and results of this analysis are given in the supplemen-
tary information.
Meta-analysis with UK BiLEVE data
Single variant associations with COPD risk and severity of
airﬂow limitation in the UK BiLEVE samples were carried out
using PLINK v1.07,21 identically to the corresponding discovery
analysis with pack-years adjustment. We carried out an inverse-
variance–weighted meta-analysis of the union of SNPs included
in the discovery exome and UK BiLEVE analyses (described in
online supplementary methods).
RESULTS
Discovery exome analysis
3226 cases and 4784 controls passed all sample and SNP geno-
type QC and were used in the exome analysis (exclusions in
online supplementary table S1). Clinical characteristics of these
samples are summarised in table 1. Of the SNPs which passed
all QC criteria in both cases and controls, 135 818 were poly-
morphic, of which 101 308 (74.6%) had a MAF<1%.
Analyses of COPD risk
We carried out pack-years adjusted analysis of COPD risk,
including 2517 cases and 3889 controls, in addition to an
unadjusted analysis, using all 3226 cases and 4784 controls
(quantile–quantile plots shown in online supplementary ﬁgure
S1). A total of four SNPs in three regions met the p<10−5 sig-
niﬁcance threshold in the pack-years adjusted analysis, with ﬁve
SNPs in four regions showing p<10−5 in the unadjusted analysis
(ﬁgure 2).
In the pack-years adjusted analysis (table 2A and ﬁgure 2A),
the most signiﬁcant association was for the previously reported
COPD/smoking region 15q25 (sentinel SNP rs8034191 OR:
1.38, MAF=34.8%, p=2.42×10−7). This signal was replicated
in the UK BiLEVE study. Two novel signals of association with
COPD risk (p<10−5) were rs3813803 within SMPDL3B (OR:
1.37, MAF=29.2%, p=1.04×10−6) and low frequency SNP
rs7269297 within MOCS3 (OR: 0.25, MAF=1.1%,
p=3.08×10−6). There was evidence of replication, just above
the Bonferroni corrected level of signiﬁcance (p<0.017) for
rs7269297 in the UK BiLEVE study (p=7.27×10−5 for
meta-analysis of discovery and UK BiLEVE results, table 2A).
A further two loci were associated with COPD risk in the
analysis unadjusted for pack-years: rs3827522 within
PRICKLE1 (OR: 0.12, MAF=0.4%, p=1.03×10−7) and
rs17368582 within MMP12 (OR: 0.712, MAF=12.2%
p=5.01×10−6, table 2A and ﬁgure 2B); however, there was no
evidence of replication of these associations with COPD risk in
UK BiLEVE. rs2276109, another SNP within MMP12,
(MAF=5.6%) which is strongly correlated with rs17368582
(r2=0.84), has previously been associated with COPD risk in
smokers.7 Overall, no associations in novel regions met exome-
wide signiﬁcance (p<3.7×10−7).
Analyses of severity of airﬂow limitation
Although no SNPs reached the p<10−5 signiﬁcance level in
either the pack-years adjusted, or the unadjusted analysis (see
online supplementary ﬁgures S2 and S3), six SNPs showed some
evidence of association (p<10−4) in one or both analyses (see
online supplementary table S2). Of note, rs28929474, the
z-allele within the SERPINA1 gene, showed modest association
in the unadjusted analysis (β=−6.17%, MAF=2.0%,
p=2.83×10−5).
UK BiLEVE meta-analysis results
Analyses of COPD risk
For the 57 234 polymorphic SNPs common to both the COPD
exome chip consortium samples and the UK BiLEVE study, a
meta-analysis of discovery and UK BiLEVE study results was
undertaken in which three regions showed association with risk
of COPD (p<10−5, ﬁgure 3, online supplementary ﬁgure S4
and table 2B). The GYPA/HHIP and GPR126 regions have previ-
ously been reported as showing association with lung function
and COPD or airﬂow limitation risk.3 10 14 The IFIT3 region
signal (rs140549288 p.Val352Leu in IFIT3, OR: 1.92,
MAF=0.7%, p=7.49×10−6) represents a novel rare variant
signal of association with COPD.
Analyses of severity of airﬂow limitation
A total of 54 168 SNPs were included in the meta-analysis of
severity of airﬂow limitation (see online supplementary ﬁgures
S5 and S6). One SNP showed association with p<10−5:
rs140198372, a variant which alters the sequence at a
site where the splicing of an intron takes place (splice site)
in SERPINA12 (β=−33.51%, MAF=0.03%, p=5.72×10−6,
table 3).
Sensitivity analyses to assess COPD case criteria
Of our 3226 COPD cases deﬁned as described above, 1398 also
had a GOLD 2 or worse COPD based on postbronchodilator
spirometry. We carried out a sensitivity analysis for all SNPs
identiﬁed in our discovery or meta-analyses of COPD risk, by
repeating the discovery analyses including only those 1398
COPD cases which underwent reversibility testing. This analysis
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showed consistent estimated effect sizes (see online supplemen-
tary table S3 and ﬁgure S7), and in particular, the ORs were not
substantially attenuated for rs7269297 in MOCS3 (sensitivity
analysis OR: 0.276; original discovery OR: 0.251), nor
rs140549288 in IFIT3 (sensitivity analysis OR: 2.554; original
discovery OR: 2.156).
Association of novel loci with smoking behaviour
Given the disparity of smoking behaviour in our cases and
control samples (table 1), we further investigated whether either
of the two novel COPD risk loci were associated with smoking
behaviour, to ascertain whether the associations with COPD
may be explained by differences in smoking. Neither of the sen-
tinel SNPs showed signiﬁcant association with heavy versus
never smoking within UK BiLEVE (p=0.956 for rs7269297
and p=0.945 for rs140549288) study. We further undertook a
look-up in the publically available results of a GWAS from the
Tobacco and Genetics consortium22 for associations with
rs7269297 in MOCS3 (rs140549288 was not available in data)
and a number of smoking traits; however, no evidence for asso-
ciation with smoking behaviour was found (cigarettes per day
p=0.610; ever vs never smoking p=0.172; current vs former
smoking p=0.699).
DISCUSSION
We carried out analyses of exome chip variants with COPD risk
and %predicted FEV1 among cases, through which we identiﬁed
a number of SNPs in both known COPD regions and at novel
loci that showed suggestive association (p<10−5) with risk of
COPD. These novel regions (region plots: online supplementary
ﬁgure S8) warrant further investigation as they may provide
insight into the underlying biological mechanisms of COPD and
airﬂow limitation in smokers and could provide novel thera-
peutic targets. The most signiﬁcant associations in both the dis-
covery exome analysis and the meta-analysis were with SNPs in
the 15q25 region, previously identiﬁed through GWAS as being
associated with smoking behaviour,22–24 lung cancer,25 COPD3
and airﬂow obstruction.14 In addition, we independently repli-
cated previously reported associations of HHIP,3 10 GPR12614
and MMP127 8 with COPD risk.
We identiﬁed novel associations between COPD risk and low
frequency or rare coding SNPs in two genes: MOCS3
Figure 2 (A) Analysis of COPD risk, with pack-years adjustment (single nucleotide polymorphisms (SNPs) with minor allele frequency (MAF)
>0.05% only; SNPs with p<10−5 highlighted). (B) Analysis of COPD risk, without pack-years adjustment (SNPs with MAF >0.05% only; SNPs with
p<10−5 highlighted).
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Table 2 Top associations in exome discovery analyses and meta-analysis of COPD risk
(A) SNPs with p<10–5 in either the pack-years adjusted or unadjusted discovery analyses
Discovery pack-years adjusted analysis (2517
cases, 3889 controls)
Discovery unadjusted analysis
(3226 cases, 4784 controls)
UK BiLEVE pack-years adjusted analysis
(4231 cases, 8979 controls)
Meta-analysis of discovery and
UK BiLEVE pack-year adjusted
analyses
MAF (MAC) Association result MAF (MAC) Association result MAF (MAC) Association result Association result
rs no. CHR Position
Coded
allele Gene Cases Controls OR (95% CI) p Value* Cases Controls OR (95% CI) p Value* Cases Controls OR (95% CI) p Value* OR (95% CI) p Value*
rs3813803 1 28282292 C SMPDL3B
(non-synonymous)
30.6%
(1541)
28.3%
(2203)
1.370 (1.207
to 1.554)
2.41×10−6 30.3%
(1956)
28.5%
(2722)
1.288 (1.160
to 1.430)
2.11×10−6 28.7%
(2418)
29.4%
(5269)
0.968 (0.911
to 1.029)
0.298 1.033 (0.978 to 1.092) 0.241
rs17368582 11 102738075 C MMP12 (synonymous) 11.1%
(561)
12.9%
(1001)
0.767 (0.642
to 0.915)
3.22×10−3 11.1%
(719)
12.8%
(1229)
0.712 (0.615
to 0.824)
5.01×10−6 12.0%
(1015)
12.2%
(2198)
0.982 (0.902
to 1.069)
0.676 0.938 (0.868 to 1.013) 0.101
rs3827522 12 42853871 A PRICKLE1
(non-synonymous)
0.2% (11) 0.4% (27) 0.184 (0.065
to 0.519)
1.39×10−3 0.2% (14) 0.5% (46) 0.123 (0.057
to 0.266)
1.03×10−7 0.3% (21) 0.3% (45) 0.907 (0.518
to 1.585)
0.731 0.633 (0.386 to 1.039) 0.071
rs8034191 15 78806023 C near AGPHD1
(intergenic)
38.0%
(1912)
32.7%
(2546)
1.374 (1.218
to 1.550)
2.42×10−7 37.7%
(2432)
32.9%
(3144)
1.364 (1.234
to 1.507)
1.18×10−9 39.2%
(3315)
35.2%
(6320)
1.156 (1.092
to 1.224)
6.85×10−7 1.193 (1.133 to 1.257) 2.79×10−11
rs7269297 20 49576664 G MOCS3
(non-synonymous)
0.7% (37) 1.4%
(110)
0.251 (0.140
to 0.448)
3.08×10−6 0.8% (54) 1.5%
(139)
0.423 (0.262
to 0.680)
3.98×10−4 1.2% (98) 1.4%
(252)
0.742 (0.578
to 0.953)
0.019 0.626 (0.497 to 0.789) 7.27×10−5
(B) SNPs with p<10–5 in the meta-analysis (only most statically significant SNP in each region shown)
Discovery pack-years adjusted analysis
(2517 cases, 3889 controls)
UK BiLEVE pack-years adjusted analysis
(4231 cases, 8979 controls)
Meta-analysis of discovery and
UK BiLEVE pack-year adjusted
analyses
MAF (MAC) Association result MAF (MAC) Association result Association result
rs no. CHR Position Coded allele Gene Cases Controls OR (95% CI) p Value* Cases Controls OR (95% CI) p Value* OR (95% CI) p Value*
rs1828591 4 145480780 A GYPA/HHIP (intergenic) 35.6% (1794) 39.1% (3042) 0.9167 (0.814, 1.032) 0.153 36.6% (3088) 40.0% (771) 0.867 (0.819, 0.918) 9.88×10−7 0.876 (0.832, 0.922) 5.75×10−7
rs4896582 6 142703877 A GPR126 (intronic) 29.3% (1473) 31.7% (2468) 0.8594 (0.757, 0.974) 0.018 28.0% (2349) 30.2% (5344) 0.879 (0.826, 0.934) 3.87×10−5 0.875 (0.827, 0.925) 2.53×10−6
rs140549288 10 91099466 C IFIT3 (exonic), LIPA (intronic) 0.8% (38) 0.6% (44) 2.156 (1.046, 4.445) 0.037 0.9% (79) 0.6% (100) 1.880 (1.378, 2.565) 6.87×10−5 1.924 (1.441, 2.560) 8.56×10−6
*p Values in bold significant at p<10−5 level.
BiLEVE, Biobank Lung Exome Variant Evaluation; MAC, minor allele count; MAF, minor allele frequency; SNPs, single nucleotide polymorphisms.
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(rs7269297, serine to alanine, MAF=1.3%, pdiscovery-
=3.08×10−6, PolyPhen prediction: benign) and IFIT3
(rs140549288, valine to leucine, MAF=0.7%, pmeta-
=8.56×10−6, PolyPhen prediction: benign). The protein
encoded by MOCS3 adenylates and activates molybdopterin
synthase, an enzyme required to synthesise molybdenum cofac-
tor26 and is expressed in bronchial epithelium and smooth
muscle layer of the bronchus.27 IFIT3 is associated with
interferon-α antiviral activity and has been found to be
up-regulated in respiratory syncytial virus infection28 and in
human lung epithelial cells infected with dengue virus.29 The
SNP rs140549288 is also located within in an intron of LIPA;
the product of this gene is involved in the hydrolysis of choles-
teryl esters and triglycerides and other SNPs within this gene
have previously been associated with coronary artery disease.30
The z-allele within the SERPINA1 gene was associated with a
lower %predicted FEV1 in cases (unadjusted analysis: pdiscovery-
=2.83×10−5); as well as being a well-established cause of AAT
deﬁciency,3 4 this SNP has also previously been associated with
an increased annual decline in FEV1 in a general population
sample31 and increased airﬂow limitation in COPD cases.32 In
the present study, the z-allele was associated with an increased
risk of COPD, although this was not statistically signiﬁcant
(OR: 1.27, p=0.252). The likely reason for the lack of a signiﬁ-
cant association with this known COPD locus is that some of
the case collections excluded individuals with AAT deﬁciency,
resulting in selection bias. In the meta-analysis of severity of
airﬂow limitation, we identiﬁed a very rare SNP within another
serine protease inhibitor gene, SERPINA12, not previously asso-
ciated with COPD (rs140198372, MAF=0.03%, pmeta-
=5.72×10−6). SERPINA12 and SERPINA1 lie 96.6 kb apart on
chromosome 14 (rs140198372 and the z-allele in SERPINA1
are not in linkage disequilibrium (r2=9.0×10−6)). SERPINA12
has been associated with cardiovascular diseases, being impli-
cated in obesity and type 2 diabetes.33
One of the primary challenges associated with identifying low
frequency variants associated with disease is limited statistical
power, and this could explain our lack of strong statistically sig-
niﬁcant ﬁndings. Indeed, none of the reported associations in
novel regions met a stringent exome-wide signiﬁcance level
(p<3.8×10−7) overall. In the present study, we would have just
54% power to detect an association with an SNP associated
with COPD risk with a MAF of 1% and an OR of 2, at the
p<3.8×10−7 level. Furthermore, recent analyses undertaken by
the UK10K Consortium found no evidence of low frequency
SNPs having large effects, upon a series of traits.34 Due to
the limited power to detect single variant associations of rare
variants with modest effect sizes, we additionally adopted
gene-based analyses using SKAT-O, a method which combines
information from several rare variants (see online supplemen-
tary information). In these analyses, we only identiﬁed one gene
meeting our elected signiﬁcance level (p<10−5); this gene-based
signal in PRICKLE1 was found however, to be driven by a single
SNP, which was identiﬁed as being associated with COPD risk in
Figure 3 Meta-analysis of COPD risk in discovery exome analysis and UK Biobank Lung Exome Variant Evaluation samples.
Table 3 Top associations (p<10−5) in meta-analysis of severity of airflow limitation
Severity of airflow limitation,
adjusted for pack-years (n=2517)
UK BiLEVE pack-years adjusted
analysis (n=4231)
Meta-analysis of
discovery and UK BiLEVE
pack-year adjusted
analyses
rs no. CHR Position
Coded
allele Gene
MAF
(MAC)
Beta
(95% CI) p Value
MAF
(MAC)
Beta
(95% CI) p Value
Beta
(95% CI) p Value
rs140198372 14 94953832 A SERPINA12
(splice site)
0.059%
(3)
−29.23
(−49.50 to
−8.96)
2.59×10−5 0.012%
(1)
−38.35
(−59.88 to
−16.82)
4.11×10−4 −33.51
(−48.27 to
−18.76)
5.72×10−6
*p Values in bold significant at p<10−5 level.
BiLEVE, Biobank Lung Exome Variant Evaluation; MAC, minor allele count; MAF, minor allele frequency.
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the single variant discovery analysis, but which was not repli-
cated in the UK BiLEVE data.
Another limitation of this study is that a number of our cases
had only prebronchodilator spirometry; for these samples, it
could not be determined whether their airﬂow limitation was
reversible, and so a proportion of these cases may not have met
the clinical deﬁnition of COPD. We undertook case–control sen-
sitivity analyses using our discovery samples, restricting cases to
the subset of 1398 individuals taken from COPD cohorts and
who had known irreversible airﬂow limitation. The effect esti-
mates of our top hits did not substantially change in this sensi-
tivity analysis, suggesting that our broader case deﬁnition,
including samples that did not undergo reversibility testing, did
not result in substantial misclassiﬁcation bias.
A further potential source of bias in this study was the heavier
smoking history in our cases compared with the control
samples. For the two SNPs identiﬁed through the analyses of
COPD risk, we found no evidence of association with smoking
in data from the UK BiLEVE study, suggesting that the associa-
tions with COPD risk were not driven by the imbalances in
smoking behaviour.
Finally, it was not possible to validate the ﬁndings of this
study through additional genotyping; however for the three
reported loci, consistent results were observed in both the dis-
covery and the UK BiLEVE samples. It would not be expected
to see the same false positive result in these two independent
samples, therefore, strengthening the evidence for these being
true associations.
In summary, we have identiﬁed potentially interesting associa-
tions with low frequency and rare SNPs and COPD risk in two
regions not previously implicated in COPD or lung function. We
further identiﬁed an association of %predicted FEV1 in indivi-
duals with COPD with a very rare SNP in SERPINA12. Further
conﬁrmation of these associations in larger independent collec-
tions of COPD cases and controls is needed. This study also pro-
vides further evidence that the z-allele within SERPINA1 may be
related to severity of airﬂow limitation in COPD. While large
sample sizes may be required to deﬁnitively identify novel loci,
we present evidence to support the notion that the genetic contri-
bution to COPD risk comprises polygenic contributions of rare,
low frequency and common genetic variants. Future studies,
alone or in combination, should aim to target the full allele fre-
quency range to unravel the genetic architecture of COPD.
Author afﬁliations
1Department of Health Sciences, University of Leicester, Leicester, UK
2William Harvey Research Institute, Barts and The London School of Medicine and
Dentistry, Queen Mary University of London, London, UK
3Division of Respiratory Medicine, University of Nottingham, Queen’s Medical Centre,
Nottingham, UK
4School of Social & Community Medicine, University of Bristol, Bristol, UK
5Department of Primary Care & Population Health, UCL, London, UK
6Population Health Research Institute, St George’s, University of London, London,
UK
7University College London, Farr Institute of Health Informatics, London, UK
8Cochrane Heart Group, London, UK
9Department of Non-communicable Disease Epidemiology, Faculty of Epidemiology
and Population Health, London School of Hygiene & Tropical Medicine, London, UK
10ISER, University of Essex, Colchester, Essex, UK
11Department of Epidemiology and Public Health, UCL, London, UK
12Institute of Cardiovascular Science, UCL, London, UK
13School of Life Sciences, University of Nottingham, Nottingham, UK
14Division of Epidemiology and Public Health, Nottingham City Hospital, University
of Nottingham, Nottingham, UK
15Cardiovascular and Diabetes Medicine, School of Medicine, University of Dundee,
Dundee, UK.
16Human Development & Health, Faculty of Medicine, University of Southampton,
Southampton General Hospital, Southampton, UK
17NIHR Southampton Respiratory Biomedical Research Unit, University of
Southampton and University Hospital Southampton NHS Foundation Trust,
Southampton General Hospital, Southampton, UK
18MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton
General Hospital, Southampton, UK
19NIHR Southampton Biomedical Research Centre, University of Southampton and
University Hospital Southampton NHS Foundation Trust, Southampton General
Hospital, Southampton, UK
20Victoria University, Wellington, New Zealand
21Respiratory Medicine Unit, Nufﬁeld Department of Medicine, University of Oxford,
Oxford, UK
22Institute for Lung Health, Department of Infection, Immunity and Inﬂammation,
University of Leicester, Leicester, UK
23National Institute for Health Research Respiratory Biomedical Research Unit,
Glenﬁeld Hospital, Leicester, UK
24Nottingham Respiratory Research Unit, University of Nottingham, City Hospital
Campus, Nottingham, UK
25Institute for Ageing and Health, Newcastle University, Campus for Ageing and
Vitality, Newcastle upon Tyne, UK
26Department of Molecular Genetics and Genomics, National Heart and Lung
Institute, Imperial College London, London, UK
27Freemasons’ Department of Geriatric Medicine, University of Auckland, New
Zealand
28Generation Scotland, Centre for Genomic and Experimental Medicine, Institute of
Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
29Division of Population Health Sciences, University of Dundee, Dundee, UK
30Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow,
UK
31Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK
32Department of Haematology, University of Cambridge, Cambridge, UK
33Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary
Disorders, King Abdulaziz University, Jeddah, Saudi Arabia
Acknowledgements This research used the ALICE and SPECTRE High
Performance Computing Facilities at the University of Leicester and was supported by
the National Institute for Health Research (NIHR) Leicester Respiratory Biomedical
Research Unit. This article/paper/report presents independent research funded
partially by the NIHR. The views expressed are those of the author(s) and not
necessarily those of the NHS, the NIHR or the Department of Health. This research
has been conducted using the UK Biobank Resource.
Contributors Case collection study concept, or data acquisition and quality
control: IS, IPH, DPS, RM, PW, JPC, AA, MC, CD, MK, JE, NK, SC, TGB, TMM,
CNAP, RT, JWH, AAS, EMD, CC, MB, BB, CB, CEB, MEJ, SGP, MFM, AJW, MJC,
BJP, BHS, SP and LH. Genotype data acquisition and QC: KES and PD.
Central study design, analysis and writing of manuscript: VEJ, IN, LVW, MDT, IPH
and IS.
Funding British Women’s Heart and Health Study is funded by the Department of
Health grant no. 90049 and the British Heart Foundation grant no. PG/09/022.
British Regional Heart Study is supported by the British Heart Foundation (grant RG/
13/16/30528). CB (COPDBEAT) received funding from the Medical Research Council
UK (grant no. G0601369), CB (COPDBEAT) and AJW (UKCOPD) were supported by
the National Institute for Health Research (NIHR Leicester Biomedical Research Unit).
MB (COPDBEAT) received funding from the NIHR (grant no. PDF-2013-06-052).
Hertfordshire Cohort Study received support from the Medical Research Council,
Arthritis Research UK, the International Osteoporosis Foundation and the British
Heart Foundation; NIHR Biomedical Research Centre in Nutrition, University of
Southampton; NIHR Musculoskeletal Biomedical Research Unit, University of Oxford.
Generation Scotland: Scottish Family Health Study is funded by the Chief Scientist
Ofﬁce, Scottish Government Health Directorates, grant number CZD/16/6 and the
Scottish Funding Council grant HR03006. EU COPD Gene Scan is funded by the
European Union, grant no. QLG1-CT-2001-01012. English Longitudinal Study of
Aging is funded by the Institute of Aging, NIH grant No. AG1764406S1. GoDARTs
is funded by the Wellcome Trust grants 072960, 084726 and 104970. MDT has
been supported by MRC fellowship G0902313. UK Biobank Lung Exome Variant
Evaluation study was funded by a Medical Research Council strategic award to MDT,
IPH, DPS and LVW (MC_PC_12010).
Competing interests None declared.
Ethics approval Several (meta-analysis design).
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/
508 Jackson VE, et al. Thorax 2016;71:501–509. doi:10.1136/thoraxjnl-2015-207876
Chronic obstructive pulmonary disease
group.bmj.com on June 23, 2016 - Published by http://thorax.bmj.com/Downloaded from 
REFERENCES
1 Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management,
and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
Am J Respir Crit Care Med 2007;176:532–55.
2 Global Strategy for the Diagnosis, Management and Prevention of COPD. 2015.
http://www.goldcopd.org/uploads/users/ﬁles/GOLD_Report_2015_Apr2.pdf
3 Pillai SG, Ge D, Zhu G, et al. A genome-wide association study in chronic
obstructive pulmonary disease (COPD): identiﬁcation of two major susceptibility loci.
PLoS Genet 2009;5:e1000421.
4 Thun GA, Imboden M, Ferrarotti I, et al. Causal and synthetic associations of
variants in the SERPINA gene cluster with alpha1-antitrypsin serum levels. PLoS
Genet 2013;9:e1003585.
5 Mayer AS, Newman LS. Genetic and environmental modulation of chronic
obstructive pulmonary disease. Respir Physiol 2001;128:3–11.
6 Soler Artigas M, Wain LV, Repapi E, et al. Effect of ﬁve genetic variants associated
with lung function on the risk of chronic obstructive lung disease, and their joint
effects on lung function. Am J Respir Crit Care Med 2011;184:786–95.
7 Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in
high-risk populations. N Engl J Med 2009;361:2599–608.
8 Haq I, Chappell S, Johnson SR, et al. Association of MMP-12 polymorphisms with
severe and very severe COPD: a case control study of MMPs-1, 9 and 12 in a
European population. BMC Med Genet 2010;11:7.
9 Cho MH, Boutaoui N, Klanderman BJ, et al. Variants in FAM13A are associated
with chronic obstructive pulmonary disease. Nat Genet 2010;42:200–2.
10 Wilk JB, Chen TH, Gottlieb DJ, et al. A Genome-wide association study of
pulmonary function measures in the Framingham Heart Study. PLoS Genet 2009;5:
e1000429.
11 Repapi E, Sayers I, Wain LV, et al. Genome-wide association study identiﬁes ﬁve loci
associated with lung function. Nat Genet 2010;42:36–44.
12 Hancock DB, Eijgelsheim M, Wilk JB, et al. Meta-analyses of genome-wide
association studies identify multiple loci associated with pulmonary function. Nat
Genet 2010;42:45–52.
13 Soler Artigas M, Loth DW, Wain LV, et al. Genome-wide association and large-scale
follow up identiﬁes 16 new loci inﬂuencing lung function. Nat Genet
2011;43:1082–90.
14 Wilk JB, Shrine NRG, Loehr LR, et al. Genome-wide association studies identify
CHRNA5/3 and HTR4 in the development of airﬂow obstruction. Am J Respir Crit
Care Med 2012;186:622–32.
15 Castaldi PJ, Cho MH, Litonjua AA, et al. The association of genome-wide signiﬁcant
spirometric loci with chronic obstructive pulmonary disease susceptibility. Am J
Respir Cell Mol Biol 2011;45:1147–53.
16 Wain L, Shrine N, Miller S, et al. Novel insights into the genetics of smoking
behaviour, lung function, and chronic obstructive pulmonary disease (UK
BiLEVE): a genetic association study in UK Biobank. Lancet Respir Med
2015;3:769–81.
17 Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample
of the general U.S. population. Am J Respir Crit Care Med 1999;159:179–87.
18 Illumina Inc. Illumina GenCall Data Analysis Software. 2005.
19 Goldstein JI, Crenshaw A, Carey J, et al. zCall: a rare variant caller for array-based
genotyping: Genetics and population analysis. Bioinformatics 2012;28:2543–5.
20 Mahajan A, Robertson N, Rayner W. Exome-Chip Quality Control SOP. Version 5,
2012-11-20. 2012.
21 Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome
association and population-based linkage analyses. Am J Hum Genet
2007;81:559–75.
22 The Tobacco and Genetics Consortium. Genome-wide meta-analyses identify
multiple loci associated with smoking behavior. Nat Genet 2010;42:441–7.
23 Thorgeirsson TE, Gudbjartsson DF, Surakka I, et al. Sequence variants at
CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet
2010;42:448–53.
24 Liu JZ, Tozzi F, Waterworth DM, et al. Meta-analysis and imputation reﬁnes the
association of 15q25 with smoking quantity. Nat Genet 2010;42:436–40.
25 McKay JD, Hung RJ, Gaborieau V, et al. Lung cancer susceptibility locus at
5p15.33. Nat Genet 2008;40:1404–6.
26 Matthies A, Nimtz M, Leimkühler S. Molybdenum cofactor biosynthesis in humans:
identiﬁcation of a persulﬁde group in the rhodanese-like domain of MOCS3 by
mass spectrometry. Biochemistry 2005;44:7912–20.
27 Uhlen M, Oksvold P, Fagerberg L, et al. Towards a knowledge-based Human
Protein Atlas. Nat Biotech 2010;28:1248–50.
28 Ternette N, Wright C, Kramer HB, et al. Label-free quantitative proteomics reveals
regulation of interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) and
50-30-exoribonuclease 2 (XRN2) during respiratory syncytial virus infection. Virol J
2011;8:442.
29 Hsu YL, Shi SF, Wu WL, et al. Protective roles of interferon-induced protein with
tetratricopeptide repeats 3 (IFIT3) in dengue virus infection of human lung epithelial
cells. PLoS ONE 2013;8:e79518.
30 Wild PS, Zeller T, Schillert A, et al. A genome-wide association study identiﬁes LIPA
as a susceptibility gene for coronary artery disease. Circ Cardiovasc Genet
2011;4:403–12.
31 Dahl M, Tybjærg-Hansen A, Lange P, et al. Change in lung function and morbidity
from chronic obstructive pulmonary disease in α1-antitrypsin MZ heterozygotes: a
longitudinal study of the general population. Ann Intern Med 2002;136:270–9.
32 Molloy K, Hersh CP, Morris VB, et al. Clariﬁcation of the risk of chronic obstructive
pulmonary disease in α1-antitrypsin deﬁciency PiMZ heterozygotes. Am J Respir Crit
Care Med 2014;189:419–27.
33 Kim DS, Burt AA, Crosslin DR, et al. Novel common and rare genetic
determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL. J Lipid Res
2013;54:552–60.
34 Walter K, Min JL, Huang J, et al., UK10K Consortium. The UK10K project identiﬁes
rare variants in health and disease. Nature 2015;526:82–90.
Jackson VE, et al. Thorax 2016;71:501–509. doi:10.1136/thoraxjnl-2015-207876 509
Chronic obstructive pulmonary disease
group.bmj.com on June 23, 2016 - Published by http://thorax.bmj.com/Downloaded from 
SERPINA12
 and IFIT3, MOCS3airflow limitation in 
identifies novel associations with COPD and 
Exome-wide analysis of rare coding variation
David P Strachan, Ian P Hall, Martin D Tobin and Louise V Wain
Padmanabhan, Lynne Hocking, Kathleen E Stirrups, Panos Deloukas,
Wardlaw, Martin J Connolly, David J Porteous, Blair H Smith, Sandosh 
E Bolton, Michelle E John, Stuart G Parker, Miriam F Moffat, Andrew J
Cyrus Cooper, Mona Bafadhel, Bethan Barker, Chris Brightling, Charlotte 
Roger Tavendale, John W Holloway, Avan A Sayer, Elaine M Dennison,
Chappell, Tamar Guetta-Baranes, Tricia M McKeever, Colin N A Palmer, 
Caroline Dale, Meena Kumari, Jorgen Engmann, Noor Kalsheker, Sally
Whincup, Juan-Pablo Casas, Antoinette Amuzu, Minkyoung Choi, 
Victoria E Jackson, Ioanna Ntalla, Ian Sayers, Richard Morris, Peter
doi: 10.1136/thoraxjnl-2015-207876
2016 71: 501-509 originally published online February 25, 2016Thorax 
 http://thorax.bmj.com/content/71/6/501
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://thorax.bmj.com/content/71/6/501
This article cites 31 articles, 3 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (968)Tobacco use
 (966)Smoking
 (1139)Health education
 (198)Open access
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on June 23, 2016 - Published by http://thorax.bmj.com/Downloaded from 
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on June 23, 2016 - Published by http://thorax.bmj.com/Downloaded from 
